

PRESS RELEASE
Uppsala
June 4, 2009

Q-Med has received 60 MUSD from Oceana Therapeutics LLC

The American anti-trust authority has not expressed any objections to the sale of Q-Med's American subsidiary, Q-Med Scandinavia, Inc. to Oceana Therapeutics, LCC. This means, amongst other things, that Oceana Therapeutics now has the global rights to market and sell the products Deflux® and Solesta™ and that Q-Med AB has received the first payment of 60 MUSD. Oceana has taken over business operations in the USA and will gradually take over the remaining markets during 2009.

The previously described transaction between Q-Med and Oceana will generate an additional payment of 15 MUSD when Solesta is approved in the USA. Provided that certain sales targets are met, Q-Med may receive further milestone payments of up to a total of 45 MUSD. Oceana will also pay a royalty for the licensing rights based on the net sales of the products. The parties will share future costs for the clinical development of Solesta in the USA.

Queries should be addressed to:

Per Langö, Senior Director Corporate Development
Tel: +46 (0)73-387 15 21
Alexander Kotsinas, Vice President and CFO
Tel: +46 (0)73-500 1111

Q-Med AB is a medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta™** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 650 coworkers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web: www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.